HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help
Market News Stocks News ETF News Crypto News

Anavex Life Sciences Corp.

Contributing Author

Recent Articles by Anavex Life Sciences Corp.

Dec-12
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease AVXL GlobeNewswire
Nov-26
Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference AVXL GlobeNewswire
Nov-25
Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update AVXL GlobeNewswire
Nov-19
Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference AVXL GlobeNewswire
Nov-18
Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025 AVXL GlobeNewswire
Nov-14
Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease AVXL GlobeNewswire
Oct-29
Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Control Group AVXL GlobeNewswire
Oct-10
Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference 'Connecting Science and Communities: The Future of Dementia Care' AVXL GlobeNewswire
Oct-02
Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX3-71 Program AVXL GlobeNewswire
Oct-02
Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX3-71 for the Treatment of Schizophrenia AVXL GlobeNewswire
Sep-30
Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer's Disease Trial AVXL GlobeNewswire
Sep-09
Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer's Disease Trial AVXL GlobeNewswire
Sep-02
Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025 AVXL GlobeNewswire
Aug-26
Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine AVXL GlobeNewswire
Aug-20
Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer's Disease AVXL GlobeNewswire
Aug-12
Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update AVXL GlobeNewswire
Aug-05
Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025 AVXL GlobeNewswire
Jul-31
Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease AVXL GlobeNewswire
May-14
Anavex Life Sciences to Participate at Upcoming Healthcare Conferences AVXL GlobeNewswire
May-13
Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update AVXL GlobeNewswire
May-06
Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025 AVXL GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.